After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Most recently, Yahoo Finance reported about the stock as it publicized that bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, BLUE falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Bluebird bio Inc is $269.84M. A total of 5.99 million shares were traded on the day, compared to an average of 13.29M shares.
In the most recent transaction, Obenshain Andrew sold 6,095 shares of BLUE for 1.53 per share on Mar 04 ’24. After the transaction, the President and CEO now owns 279,998 company shares. In a previous transaction on Mar 04 ’24, Klima Thomas J sold 4,573 shares at 1.53 per share. BLUE shares that the insider owns now total 124,840.
Among the insiders who sold shares, Colvin Richard A disposed of 6,770 shares on Mar 01 ’24 at a per-share price of $1.53. This resulted in the Chief Medical Officer holding 118,368 shares of BLUE after the transaction. In another insider transaction, Vittiglio Joseph sold 5,217 shares at $0.90 per share on Feb 05 ’24. Company shares held by the Chief Business & Legal Officer now total 44,783.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, BLUE has a high of $5.53 and a low of $0.88.
As of this writing, BLUE has an earnings estimate of -$0.66 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$0.38 per share and a lower estimate of -$0.98. The company reported an EPS of -$0.67 in the last quarter, which was 6.90% higher than expectations of -$0.72.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. BLUE’s latest balance sheet shows that the firm has $299.50M in Cash & Short Term Investments as of fiscal 2021. There were $89.58M in debt and $152.99M in liabilities at the time. Its Book Value Per Share was $2.08, while its Total Shareholder’s Equity was $374.28M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BLUE is Buy with a score of 3.50.
